Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;8(62):105458-105462.
doi: 10.18632/oncotarget.22246. eCollection 2017 Dec 1.

Predicting castration-resistant prostate cancer after combined androgen blockade

Miao He  1 , Haina Liu  1 , Jingyi Cao  2 , Qian Wang  2 , Haiting Xu  3 , Yufeng Wang  1
Affiliations

Predicting castration-resistant prostate cancer after combined androgen blockade

Miao He et al. Oncotarget. .

Abstract

This study analyzed 99Tcm-MDP bone scans and investigated factors influencing early-stage castration resistance in prostate cancer (CRPC) patients with bone metastasis. We retrospectively analyzed clinical data from 92 patients with bone metastatic prostate cancer treated with maximal androgen blockade. Patients were imaged with 99Tcm-MDP bone scan to detect metastases, and prostate specific antigen (PSA) values were measured regularly. Before treatment, 464 total bone metastases were detected in the 92 patients, with pelvic bone metastases accounting for about 30.6% of the total. After combined androgen blockade treatment, median CRPC occurrence time was 23 months. A longer time to reach the lowest PSA value was an independent predictor of early-onset CRPC (occurrence <1 year after treatment). Our findings suggest that 99Tcm-MDP bone scans are useful for diagnosing prostate cancer bone metastasis and grading. Patients with Gleason scores>8, higher PSA values after treatment, and shorter times to reach the lowest PSA value had poorer responses to combined androgen blockade treatment.

Keywords: bone metastasis; bone scan; castration resistance; combined androgen blockade; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131. - PubMed
    1. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566–577. - PubMed
    1. McLoughlin LC, O'Kelly F, O'Brien C, Sheikh M, Feeney J, Torreggiani W, Thornhill JA. The improved accuracy of planar bone scintigraphy by adding single photon emission computed tomography (SPECT-CT) to detect skeletal metastases from prostate cancer. Ir J Med Sci. 2016;185:101–105. - PubMed
    1. Chen YH, Nie P, Jiang W, Zhao SJ, Zhang Z, Lin HX, Li MY, Liu YQ, Li PH, Zhu XS. [Predictive factors for bone metastases of prostate cancer]. [Article in Chinese] Nan Fang Yi Ke Da Xue Xue Bao. 2016;36:205–209. - PubMed